[go: up one dir, main page]

MA32030B1 - Vaccins anti-malaria - Google Patents

Vaccins anti-malaria

Info

Publication number
MA32030B1
MA32030B1 MA33035A MA33035A MA32030B1 MA 32030 B1 MA32030 B1 MA 32030B1 MA 33035 A MA33035 A MA 33035A MA 33035 A MA33035 A MA 33035A MA 32030 B1 MA32030 B1 MA 32030B1
Authority
MA
Morocco
Prior art keywords
antigen
component
immunogenic particle
stabilizing agent
relates
Prior art date
Application number
MA33035A
Other languages
Arabic (ar)
English (en)
Inventor
Dominique Ingrid Lemoine
Florence Emilie Jeanne Francoise Wauters
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40584700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32030(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA32030B1 publication Critical patent/MA32030B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un constituant de vaccin anti-malaria comprenant: (a) une particule immunogène rts, s et/ou (b) une particule immunogène dérivée de la protéine cs d'une ou plusieurs souches de p. Vivax et l'antigène s de l'hépatite b et éventuellement l'antigène n non fusionné ou (c) une particule immunogène comprenant rts, csv-s et l'antigène s éventuellement non fusionné et (d) un agent stabilisant consistant en un agent stabilisant comportant au moins un groupe thiol fonctionnel ou leurs mélanges. Elle concerne également des méthodes servant à préparer ce constituant, son utilisation médicale en particulier pour la prophylaxie d'infections malariennes, des compositions/vaccins contenant ce constituant et l'utilisation, en particulier thérapeutique, de ce dernier
MA33035A 2007-12-21 2010-07-19 Vaccins anti-malaria MA32030B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1576207P 2007-12-21 2007-12-21
PCT/EP2008/067925 WO2009080715A2 (fr) 2007-12-21 2008-12-18 Vaccins anti-malaria

Publications (1)

Publication Number Publication Date
MA32030B1 true MA32030B1 (fr) 2011-01-03

Family

ID=40584700

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33035A MA32030B1 (fr) 2007-12-21 2010-07-19 Vaccins anti-malaria

Country Status (22)

Country Link
US (1) US20100272745A1 (fr)
EP (1) EP2234637A2 (fr)
JP (1) JP2011507816A (fr)
KR (1) KR20100109556A (fr)
CN (1) CN102026657A (fr)
AP (1) AP2010005296A0 (fr)
AR (1) AR071741A1 (fr)
AU (1) AU2008339980A1 (fr)
BR (1) BRPI0822098A2 (fr)
CA (1) CA2708716A1 (fr)
CL (1) CL2008003808A1 (fr)
CO (1) CO6300963A2 (fr)
CR (1) CR11577A (fr)
DO (1) DOP2010000189A (fr)
IL (1) IL206308A0 (fr)
MA (1) MA32030B1 (fr)
MX (1) MX2010006984A (fr)
PE (1) PE20091528A1 (fr)
TW (1) TW200940086A (fr)
UY (1) UY31569A1 (fr)
WO (1) WO2009080715A2 (fr)
ZA (1) ZA201004304B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013142278A1 (fr) * 2012-03-22 2013-09-26 New York University Compositions vaccinales contre plasmodium vivax
WO2016184784A1 (fr) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides comprenant le domaine de liaison des protéines de plasmodium falciparum (cbp1 et cbp2) à cx3cl1 de chimiokine
EP3370730A4 (fr) 2015-11-06 2019-07-31 Adjuvance Technologies, Inc. Analogues de saponine triterpénique
CN105233296B (zh) * 2015-11-24 2018-08-17 江苏省农业科学院 用于鸭病毒性肝炎活疫苗的耐热冻干保护剂及其制备方法和应用
GB201608821D0 (en) * 2016-05-19 2016-07-06 Isis Innovation Vaccines
CN110730666A (zh) * 2017-04-25 2020-01-24 佐剂技术公司 三萜皂苷类似物
SG10202108075YA (en) * 2017-04-25 2021-09-29 Adjuvance Technologies Inc Triterpene saponin analogues
US11324821B2 (en) 2017-10-16 2022-05-10 Adjuvance Technologies, Inc. Triterpene saponin analogues
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819209D0 (en) * 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
AU2088992A (en) * 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
ZA973642B (en) * 1996-04-26 1997-11-25 Merck & Co Inc DNA vaccine formulations.
JP4386965B2 (ja) * 1996-04-26 2009-12-16 メルク エンド カンパニー インコーポレーテッド Ｄｎａワクチン製剤
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
EP1279401B1 (fr) * 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Emulsions du type huile-dans-l'eau contenant des saponines
CA2375829A1 (fr) * 1999-06-02 2000-12-07 Human Genome Sciences, Inc. Formulations a base de fecteur de croissance keratinocytaire 2
EP1689434A1 (fr) * 2003-11-21 2006-08-16 Pfizer Products Inc. L'utilisation d'antibiotiques comme adjuvants de vaccins
JP2008507474A (ja) * 2004-02-02 2008-03-13 タノックス インコーポレイテッド 新規のＩｇＥエピトープの同定
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
CN101432016A (zh) * 2005-12-15 2009-05-13 Aeras全球Tb疫苗基金会 减毒的分枝杆菌的新引发-加强组合
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions

Also Published As

Publication number Publication date
AP2010005296A0 (en) 2010-06-30
DOP2010000189A (es) 2010-08-15
CR11577A (es) 2010-09-03
JP2011507816A (ja) 2011-03-10
EP2234637A2 (fr) 2010-10-06
AR071741A1 (es) 2010-07-14
ZA201004304B (en) 2012-11-28
PE20091528A1 (es) 2009-10-29
WO2009080715A2 (fr) 2009-07-02
WO2009080715A3 (fr) 2009-11-12
US20100272745A1 (en) 2010-10-28
CO6300963A2 (es) 2011-07-21
AU2008339980A1 (en) 2009-07-02
IL206308A0 (en) 2010-12-30
TW200940086A (en) 2009-10-01
UY31569A1 (es) 2009-08-03
MX2010006984A (es) 2010-10-25
CA2708716A1 (fr) 2009-07-02
BRPI0822098A2 (pt) 2015-06-30
CL2008003808A1 (es) 2011-03-11
CN102026657A (zh) 2011-04-20
KR20100109556A (ko) 2010-10-08

Similar Documents

Publication Publication Date Title
MA32030B1 (fr) Vaccins anti-malaria
WO2020128031A3 (fr) Arn pour vaccins antipaludiques
NO20090178L (no) Vaksiner for malaria
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MA30581B1 (fr) Vaccin viral recombinant
WO2007030810A3 (fr) Moniteur de sang total multiparametrique et procede associe
MA40151A1 (fr) Vaccins de recombinaison fmdv et leurs utilisations
CY1112851T1 (el) Μεθοδος προληψης ή θεραπειας μολυνσης μ. τuβεrculosis
MA29458B1 (fr) Composition de vaccin
MX349481B (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CY1112879T1 (el) Συνθεση εμβολιου
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
BR0204470A (pt) Uso de flavivirus para a expressão de epitopos de proteìna e para o desenvolvimento de um novo virus vacinal vivo atenuado para imunização contra flavivirus e outros agentes infecciosos
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MA27699A1 (fr) Vaccin contre vhc
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
UY31574A1 (es) Vacunas contra la malaria
DE60304989D1 (de) Zusammensetzungen enthaltend fötales Hämoglobin und bakterielles Endotoxin und fakultativ zusätzliche fötale Leberkomponenten
EA202090287A1 (ru) Составы пролонгированного действия
UA95293C2 (en) Vaccines for malaria